As run-up to FDA’s DTC Prescription Advertising Rule that goes into effect on May 20, 2024, CHC is working with FDA staff to help reinforce current ad review processes available to healthcare marketers and how review of ads will change in May and later this year with its November enforcement date. Watch for our planned […]
Read more The FDA’s final rule for Direct-to-Consumer Prescription Drug Advertisements (released on November 21, 2023) will certainly impact the creative decisions agencies will make about how to structure the agency refers to as the “major statement” or the dual modality of presenting in a balanced or “neutral” manner the drug’s benefits and risks in visually clear, […]
Read more
Dec. 15, 2016 – Television ads allegedly making false and misleading claims about the risks associated with their products were cited by the FDA’s Office of Prescription Drug Promotion (OPDP) in Untitled Letters issued Dec. 12 to Celgene Corp. and Sanofi-US. These letters bring the total number of Untitled Letters issued this year up to […]
Read more